The FDA has opened applications for its new expedited investigational new drug (IND) pilot program, as part of the agency’s “Operation Trialblazer.” Newly appointed permanent directors Karim Mikhail and Michael Davis said the agency incorporated public feedback into eligibility requirements as it aims to speed the earliest steps of bringing therapies into human testing. In parallel, the FDA also launched the broader pilot framework to partner drugmakers with research institutions, with the goal of moving promising programs into clinical trials faster while maintaining appropriate oversight. Together, the announcements signal a renewed push to shorten timelines for early clinical entry. For biotech teams, the message is clear: early planning for IND readiness and a stronger understanding of pilot eligibility could become a near-term lever for faster trial start times, particularly for development-stage companies looking to reduce preclinical-to-clinic drag.